Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal
R&D-Focused Collaboration
Executive Summary
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.